A Heritage of Improving Lives Through Innovation

Our company’s legacy of innovation began in the early 1800s, when our founders made it their mission to bring better health solutions to patients who needed them most. Today, we are continuing that tradition by using the latest science and technology to help improve lives through the research and development of new medicines for serious diseases.
History Timeline Top Banner,History Timeline Top Banner
EA4C17

Explore Our History

A LIFETIME OF INNOVATION IN SCIENCE AND MEDICINE BEGINS
A LIFETIME OF INNOVATION IN SCIENCE AND MEDICINE BEGINS

1819

A LIFETIME OF INNOVATION IN SCIENCE AND MEDICINE BEGINS

Edward Robinson Squibb was born in Wilmington, Delaware, on July 4, 1819. 

Early in his life, Edward dreamed of becoming a physician. To make this possible, he served five years as an apothecary’s apprentice in Philadelphia, Pennsylvania, and from his meager pay he saves enough to enter Jefferson Medical College.

1845

EDWARD ROBINSON SQUIBB

Dr. Squibb graduates from Philadelphia’s Jefferson Medical College. He spends a decade as a surgeon in the U.S. Navy, an experience that impresses upon him the urgent need for high-quality, standardized medicines. 

EDWARD ROBINSON SQUIBB

1845

EDWARD ROBINSON SQUIBB

Dr. Squibb graduates from Philadelphia’s Jefferson Medical College. He spends a decade as a surgeon in the U.S. Navy, an experience that impresses upon him the urgent need for high-quality, standardized medicines. 

Dr. Squibb
Dr. Squibb

1847

SQUIBB’S QUEST FOR PURITY 

Dr. Squibb makes his mark as a forceful crusader against the impure drugs of the times. At the government’s request, he establishes a laboratory for the Naval Hospital in Brooklyn, New York, and serves as its director.

1852

ETHER PRODUCTION

While at the Naval Hospital, Dr. Squibb develops a better way to produce ether and shares his discovery with the rest of the medical community. His success at producing ether using steam distillation helps thousands of surgical patients who were suffering through operations without the benefit of anesthesia. Dr. Squibb is encouraged by the government to establish his own firm to aid the armed forces.

Ether Production

1852

ETHER PRODUCTION

While at the Naval Hospital, Dr. Squibb develops a better way to produce ether and shares his discovery with the rest of the medical community. His success at producing ether using steam distillation helps thousands of surgical patients who were suffering through operations without the benefit of anesthesia. Dr. Squibb is encouraged by the government to establish his own firm to aid the armed forces.

FIRST LABORATORY
FIRST LABORATORY

1858

FIRST LABORATORY

Dr. Squibb rents a brownstone in Brooklyn, New York, for his new business and begins pharmaceutical manufacturing operations. In December, he is severely burned in an ether fire that nearly destroys his business.

1860

WILLIAM MCLAREN BRISTOL 

Born in Clinton, New York, on July 28, 1860.

WILLIAM MCLAREN BRISTOL

1860

WILLIAM MCLAREN BRISTOL 

Born in Clinton, New York, on July 28, 1860.

First Quality Control Laws
First Quality Control Laws

1860

FIRST QUALITY CONTROL LAWS
 
Dr. Squibb receives appointment to the Committee of Revision of the U.S. Pharmacopeia. He indicates to committee members what formulas can be accepted, improved, or dropped altogether—creating a “quality control” for the first time.

1861–1865

SQUIBB MEDICINE CHEST

During the Civil War, Squibb manufactures compact, portable chests for military surgeons that contain an array of medicines and equipment—from ether and morphine to bandages and sponges. Each chest costs about $100, the equivalent of several thousand dollars today. 

 

 

SQUIBB MEDICINE CHEST

1861–1865

SQUIBB MEDICINE CHEST

During the Civil War, Squibb manufactures compact, portable chests for military surgeons that contain an array of medicines and equipment—from ether and morphine to bandages and sponges. Each chest costs about $100, the equivalent of several thousand dollars today. 

 

 

First Drug Regulations
First Drug Regulations

1862

FIRST DRUG REGULATIONS

With Dr. Squibb’s untiring concern for the use of quality drugs, he justifies his criticism of the American Pharmaceutical Society for its continued failure to enforce the Act of 1848—an Act which prohibits the import of adulterated drugs.

Dr. Squibb expands his business and construction begins on a new laboratory building on nearby Doughty Street in Brooklyn.

1864

JOHN RIPLEY MYERS

Born in Cleveland, Ohio, on October 8, 1864.

JOHN RIPLEY MYERS

1864

JOHN RIPLEY MYERS

Born in Cleveland, Ohio, on October 8, 1864.

Squibb's High Standards
Squibb's High Standards

1872

SQUIBB’S HIGH STANDARDS

Dr. Squibb’s meticulousness impacts the medicine and pharmaceutical industries at large. His maxim was: “Look at the bottle, look at the label, look before you fill, look when you have filled.”

1879

DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

Dr. Squibb presents a report to the New York State Medical Society, “Proposed Law to Prevent the Adulteration of Food and Medicine and to Create a State Board of Health.” Known as the Squibb Bill, it becomes law and serves as the basis for the Federal Pure Food and Drug Act of 1906. 

DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

1879

DR. SQUIBB’S PROPOSAL FOR SAFE MEDICINE

Dr. Squibb presents a report to the New York State Medical Society, “Proposed Law to Prevent the Adulteration of Food and Medicine and to Create a State Board of Health.” Known as the Squibb Bill, it becomes law and serves as the basis for the Federal Pure Food and Drug Act of 1906. 

SQUIBB MEDICAL JOURNAL
SQUIBB MEDICAL JOURNAL

1882

SQUIBB MEDICAL JOURNAL 

Dr. Squibb introduces a bi-monthly publication called Ephemeris. Written for physicians, the magazine offers information on new pharmaceutical developments. It also attacks what he considers to be “quack” medicine—one of his life-long obsessions.

1887

CLINTON PHARMACEUTICALS

William Bristol and John Myers invest $5,000 to purchase the failing Clinton Pharmaceutical Company. With a pledge to sell no “quack remedies,” the two quickly turn the business around.

CLINTON PHARMACEUTICALS

1887

CLINTON PHARMACEUTICALS

William Bristol and John Myers invest $5,000 to purchase the failing Clinton Pharmaceutical Company. With a pledge to sell no “quack remedies,” the two quickly turn the business around.

Clinton Pharmaceutical Company Catalog
Clinton Pharmaceutical Company Catalog

1888

CLINTON PHARMACEUTICAL COMPANY CATALOG 

Clinton Pharmaceutical Company promotes 1,800 products in their first catalog, including “gelatin coated pills and granules, compressed tablets, tablet triturates, hypodermic tablets, tinctures, elixirs, wines and syrups.”

1892

E.R. SQUIBB & SONS FORMED

Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons. The company has capital assets of $1.5 million, according to the Articles of Incorporation filed in 1895. 

E.R. SQUIBB & SONS FORMED

1892

E.R. SQUIBB & SONS FORMED

Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons. The company has capital assets of $1.5 million, according to the Articles of Incorporation filed in 1895. 

FIRST BREAKTHROUGH PRODUCT

1895

FIRST BREAKTHROUGH PRODUCT

Marketed as a tonic and laxative, Sal Hepatica salts, dubbed the “poor man’s spa,” mimic the taste and effect of the natural mineral waters of a Bohemian spa. Within a decade, annual sales rise to a half-million dollars. The product is a mainstay of Bristol Myers until 1974. 

BRISTOL, MYERS COMPANY
BRISTOL, MYERS COMPANY

1899

BRISTOL, MYERS COMPANY

Bristol and Myers rename their business the Bristol, Myers Company, which outgrows its home in Clinton, New York. The company relocates — first to Syracuse and then, in 1899, to Brooklyn to better serve customers in New England and Pennsylvania.

IPANA

1901

IPANA

Bristol Myers introduces Ipana toothpaste, featuring a disinfectant to prevent tooth decay and gum disease. 

1902

SQUIBB QUALITY-CONTROL LABORATORY

E.R. Squibb & Sons establishes its first quality-control laboratory. Soon, it has nearly 100 employees and produces over 800 preparations. 

SQUIBB QUALITY CONTROL LABORATORY

1902

SQUIBB QUALITY-CONTROL LABORATORY

E.R. Squibb & Sons establishes its first quality-control laboratory. Soon, it has nearly 100 employees and produces over 800 preparations. 

NEW JERSEY PLANT
NEW JERSEY PLANT

1905

NEW JERSEY PLANT

E.R. Squibb & Sons purchases an ether manufacturing plant in what was then the wilds of New Brunswick, New Jersey. 

1906

PURE FOOD AND DRUG ACT

President Theodore Roosevelt signs the Pure Food and Drug Act of 1906 into law. Although Dr. Squibb died in 1900, the act is a triumph of his lifelong crusade for safe, reliable pharmaceutical products. 

GROWING IN NEW JERSEY

Bristol Myers purchases seven acres in Hillside, New Jersey, for expanded production of Sal Hepatica. 

PURE FOOD AND DRUG ACT

1906

PURE FOOD AND DRUG ACT

President Theodore Roosevelt signs the Pure Food and Drug Act of 1906 into law. Although Dr. Squibb died in 1900, the act is a triumph of his lifelong crusade for safe, reliable pharmaceutical products. 

GROWING IN NEW JERSEY

Bristol Myers purchases seven acres in Hillside, New Jersey, for expanded production of Sal Hepatica. 

Squibb Biologics
Squibb Biologics

1914

SQUIBB BIOLOGICS 

Squibb Biological Laboratories division produces antitoxins, serums and vaccines.

E.R. Squibb & Sons serves as the primary supplier of ether during WWI.

DIGITALIS

1917

DIGITALIS

E.R. Squibb & Sons pioneers the standardization of digitalis, derived from the foxglove plant as an early treatment for heart conditions.

1919

SQUIBB EXPANSION 

E.R. Squibb & Sons product line grows to 2,382 items sold in 6,547 packages, including newly-introduced veterinary medicines. The company expands westward by opening a distribution center in Chicago, and also organizes an export department in Brooklyn—establishing itself as a leader in international trade.

Squibb Expansion

1919

SQUIBB EXPANSION 

E.R. Squibb & Sons product line grows to 2,382 items sold in 6,547 packages, including newly-introduced veterinary medicines. The company expands westward by opening a distribution center in Chicago, and also organizes an export department in Brooklyn—establishing itself as a leader in international trade.

SQUIBB COMMITMENT TO BETTER HEALTH
SQUIBB COMMITMENT TO BETTER HEALTH

1920

SQUIBB COMMITMENT TO BETTER HEALTH 

E.R. Squibb & Sons produces vaccines during the first decades of the 20th century, helping to protect an entire generation—while laying the foundation for the modern pharmaceutical industry. These revolutionary vaccines were possible due to the wide acceptance of germ theory in the late 1800s. For the first time, common ailments like diphtheria, tuberculosis, tetanus and typhoid fever could be prevented.

1921

SQUIBB’S “PRICELESS INGREDIENT”

By 1921, E.R. Squibb & Sons produces over-the-counter home remedies like bicarbonate of soda, castor oil, milk of magnesia and Epsom salts.

An advertising campaign is now needed to reach consumers, without offending the publicity-shy medical profession.

A young copywriter hits on the concept “Priceless Ingredient,” and unveils a classic of American advertising.

Squibb's Priceless Ingredient

1921

SQUIBB’S “PRICELESS INGREDIENT”

By 1921, E.R. Squibb & Sons produces over-the-counter home remedies like bicarbonate of soda, castor oil, milk of magnesia and Epsom salts.

An advertising campaign is now needed to reach consumers, without offending the publicity-shy medical profession.

A young copywriter hits on the concept “Priceless Ingredient,” and unveils a classic of American advertising.

BRISTOL MYERS GOES PUBLIC
BRISTOL MYERS GOES PUBLIC

1929

BRISTOL MYERS GOES PUBLIC

Gross profits top $1 million and the company’s products are sold in 26 countries. Bristol Myers becomes a publicly held firm on the New York Stock Exchange. 

1938

SQUIBB INSTITUTE FOR MEDICAL RESEARCH

Squibb furthered its commitment to innovative research by opening the 52,000-square foot Squibb Institute for Medical Research in New Brunswick, New Jersey.

SQUIBB INSTITUTE FOR MEDICAL RESEARCH

1938

SQUIBB INSTITUTE FOR MEDICAL RESEARCH

Squibb furthered its commitment to innovative research by opening the 52,000-square foot Squibb Institute for Medical Research in New Brunswick, New Jersey.

INTOCOSTRIN

1939

INTOCOSTRIN

Squibb researchers develop a new method for preparing curare and provide free samples of Intocostrin to clinical researchers, who find the curare extract helpful in relaxing the muscles of surgical patients.

CHEPLIN BIOLOGICAL LABORATORIES
CHEPLIN BIOLOGICAL LABORATORIES

1943

CHEPLIN BIOLOGICAL LABORATORIES 

Bristol Myers acquires Cheplin Laboratories in Syracuse, New York, enabling it to mass produce penicillin during World War II. This marks the company’s entry into ethical drug development. 

1944

PENICILLIN PRODUCTION PLANT

Squibb opens the world’s largest penicillin production facility in New Brunswick, New Jersey.

PENICILLIN PRODUCTION PLANT

1944

PENICILLIN PRODUCTION PLANT

Squibb opens the world’s largest penicillin production facility in New Brunswick, New Jersey.

FLO-CILLIN ‘96’

1948

FLO-CILLIN ‘96’

Bristol Laboratories introduces Flo-Cillin 96, a long-lasting injectable penicillin.

NEW PAIN RELIEVER

Bufferin is also introduced.

SQUIBB RECEIVES THE LASKER AWARD
SQUIBB RECEIVES THE LASKER AWARD

1955

SQUIBB RECEIVES THE LASKER AWARD

Squibb and Hoffman-La Roche share the Lasker Award for their work on the anti-tubercular agent isoniazid. This is the first time the Lasker Award is bestowed on the pharmaceutical industry.

1956

EARLY CANCER RESEARCH

Bristol Myers Squibb enters the cancer drug development field, building on collaborations around promising antibiotics with the Microbial Chemistry Research Foundation of Japan.

EARLY CANCER RESEARCH

1956

EARLY CANCER RESEARCH

Bristol Myers Squibb enters the cancer drug development field, building on collaborations around promising antibiotics with the Microbial Chemistry Research Foundation of Japan.

CLAIROL PURCHASED
CLAIROL PURCHASED

1959

CLAIROL PURCHASED

Bristol Myers acquires the hair-coloring company Clairol, which was founded in 1931 by Joan and Lawrence M. Gelb. Their son, Richard L. Gelb, would later serve as Bristol Myers’ president, CEO and Chairman of the Board.

1966

NEW LABORATORY

Ground is broken for the construction of Bristol Myers Products research and development laboratories in Hillside, New Jersey. It is the largest proprietary laboratory in the world.

NEW LABORATORY

1966

NEW LABORATORY

Ground is broken for the construction of Bristol Myers Products research and development laboratories in Hillside, New Jersey. It is the largest proprietary laboratory in the world.

MEAD JOHNSON & COMPANY
MEAD JOHNSON & COMPANY

1967

MEAD JOHNSON & COMPANY

Bristol-Myers acquires Mead Johnson, maker of Enfamil baby formulas and other nutritional products. Pharmaceuticals included early anti-cancer drugs Megace and Cytoxan.

1967

Anti-Cancer Treatment

Squibb researchers develop HYDREA® (hydroxyurea), the company’s first anti-cancer treatment.

1971

SQUIBB HEADQUARTERS ESTABLISHED

Squibb establishes worldwide headquarters in Princeton, New Jersey, and expands facilities for the Squibb Institute for Medical Research. This allows Squibb to make more groundbreaking discoveries and advancements.

SQUIBB HEADQUARTERS ESTABLISHED

1971

SQUIBB HEADQUARTERS ESTABLISHED

Squibb establishes worldwide headquarters in Princeton, New Jersey, and expands facilities for the Squibb Institute for Medical Research. This allows Squibb to make more groundbreaking discoveries and advancements.

PALOMAR PICTURES INTERNATIONAL
PALOMAR PICTURES INTERNATIONAL

1972

PALOMAR PICTURES INTERNATIONAL

Bristol Myers announces the formation of Palomar Pictures International. Palomar produces several films, including The Stepford Wives and The Taking of Pelham One Two Three. The company exits the film business two years later.

1973

PRODUCT APPROVAL

Bristol Laboratories introduces MUTAMYCIN® (mytomycin) for the treatment of bone cancer and stomach and pancreatic tumors.

1974

PRODUCT APPROVAL

Bristol Laboratories introduces cancer chemotherapy agent Blenoxane® (bleomycin sulfate) for the treatment of squamous cell cancers, head and neck cancers and Hodgkin’s and non-Hodgkin’s lymphomas.

1975

PRODUCT APPROVAL

Squibb researchers develop CAPOTEN® (captopril), the first ACE inhibitor for hypertension and later heart failure

1976

PRODUCT APPROVAL

FDA approves CeeNU® (lomustine) and BICNU® (carmustine).

1978

CREATION OF CONVATEC

ConvaTec is formed by Squibb to market ostomy and wound therapy products.

CREATION OF CONVATEC

1978

CREATION OF CONVATEC

ConvaTec is formed by Squibb to market ostomy and wound therapy products.

1979

PRODUCT APPROVAL

PLATINOL® (cisplatin) becomes the first platinum-containing anti-cancer drug for testicular cancer. 

1983

PRODUCT APPROVAL

The FDA approves Bristol Laboratories VePesid® (etoposide) for patients with testicular cancer that have not responded to standard chemotherapy.

BRISTOL MYERS RESEARCH COMPLEX OPENS
BRISTOL MYERS RESEARCH COMPLEX OPENS

1986

BRISTOL MYERS RESEARCH COMPLEX OPENS

Bristol Myers opens a state-of-the-art research complex in Wallingford, Connecticut, housing more than 800 scientists and support staff. In 1995, it is named the Richard L. Gelb Center for Pharmaceutical Research and Development after the former chairman and CEO. 

1986

CELGENE FOUNDED 

Celgene is founded by David Stirling, Ph.D. and Sol Barer, Ph.D. as an independent biotechnology company. 

Celgene Founded

1986

CELGENE FOUNDED 

Celgene is founded by David Stirling, Ph.D. and Sol Barer, Ph.D. as an independent biotechnology company. 

1986

PRODUCT APPROVAL

BUSPAR, discovered by Bristol Myers neuroscience researchers, is approved for the treatment of generalized anxiety disorder.

BRISTOL MYERS AND SQUIBB MERGE
BRISTOL MYERS AND SQUIBB MERGE

1989

BRISTOL MYERS AND SQUIBB MERGE

Bristol Myers merges with Squibb, creating a global leader in the health care industry. The merger creates Bristol Myers Squibb, the world’s second-largest pharmaceutical enterprise. One of the first medicines the new company introduces is PARAPLATIN, approved for treating recurrent ovarian cancer.

1991

Product Approval

1993

THALIDOMIDE ADAPTATION  

Scientists research and develop numerous compounds based on the structure of thalidomide, licensed by Celgene from Rockefeller University in 1992. 

THALIDOMIDE ADAPTATION

1993

THALIDOMIDE ADAPTATION  

Scientists research and develop numerous compounds based on the structure of thalidomide, licensed by Celgene from Rockefeller University in 1992. 

1995

PRODUCT APPROVAL

ZERIT® (stavudine) is approved for treating HIV/AIDS.

1995

PRODUCT APPROVAL 
RESEARCH CAMPUS OPENS
RESEARCH CAMPUS OPENS

1997

RESEARCH CAMPUS OPENS

Bristol Myers Squibb opens a 433-acre research campus in Hopewell, New Jersey.  

1997

PRODUCT APPROVAL 

1998

NATIONAL MEDAL OF TECHNOLOGY

President Bill Clinton awards the National Medal of Technology — America’s highest honor for technological innovation — to Bristol Myers Squibb "for extending and enhancing human life through innovative pharmaceutical research and development, and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry." 

NATIONAL MEDAL OF TECHNOLOGY

1998

NATIONAL MEDAL OF TECHNOLOGY

President Bill Clinton awards the National Medal of Technology — America’s highest honor for technological innovation — to Bristol Myers Squibb "for extending and enhancing human life through innovative pharmaceutical research and development, and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry." 

SECURE THE FUTURE INITIATIVE ANNOUNCED
SECURE THE FUTURE INITIATIVE ANNOUNCED

1999

SECURE THE FUTURE INITIATIVE ANNOUNCED

The Bristol Myers Squibb Foundation announces SECURE THE FUTURE®, a $100 million commitment to advance HIV/AIDS research and community outreach programs in seven African countries: Botswana, Namibia, Lesotho, Swaziland, Uganda, Burkina Faso and Tanzania. 

2001

CHILDREN’S HOSPITAL OPENS

The Bristol Myers Squibb Children’s Hospital opens as part of Robert Wood Johnson University Hospital in New Brunswick, New Jersey. The first freestanding children’s hospital in the state, it offers care without regard to a family’s ability to pay and offers more than 45 pediatric specialties.

DUPONT PHARMACEUTICALS PURCHASED 

DuPont pharmaceuticals is acquired, strengthening Bristol Myers Squibb’s HIV and cardiovascular businesses while also adding medical imaging. 

CHILDREN’S HOSPITAL OPENS

2001

CHILDREN’S HOSPITAL OPENS

The Bristol Myers Squibb Children’s Hospital opens as part of Robert Wood Johnson University Hospital in New Brunswick, New Jersey. The first freestanding children’s hospital in the state, it offers care without regard to a family’s ability to pay and offers more than 45 pediatric specialties.

DUPONT PHARMACEUTICALS PURCHASED 

DuPont pharmaceuticals is acquired, strengthening Bristol Myers Squibb’s HIV and cardiovascular businesses while also adding medical imaging. 

2001

PRODUCT ACQUISITION   

2001

PRODUCT APPROVAL 

FDA approves FOCALIN® (dexmethylphenidate)

2002

PRODUCT APPROVAL

FDA approves ABILIFY® (aripiprazole). 

2003

PRODUCT APPROVAL

FDA approves REYATAZ® (atazanavir).

CELGENE AND ANTHROGENSIS MERGE
CELGENE AND ANTHROGENSIS MERGE

2003

CELGENE AND ANTHROGENSIS MERGE 

Celgene acquires Anthrogenesis and renames the unit Celgene Cellular Therapies (CCT). 

2003

Children’s Clinical Center of Excellence

The first Children’s Clinical Center of Excellence—devoted to treating children with HIV/AIDS and their families—opens in Botswana. This joint effort with the Baylor International Pediatric AIDS Initiative is the first of four centers to become operational in Africa.

Children’s Clinical Center of Excellence

2003

Children’s Clinical Center of Excellence

The first Children’s Clinical Center of Excellence—devoted to treating children with HIV/AIDS and their families—opens in Botswana. This joint effort with the Baylor International Pediatric AIDS Initiative is the first of four centers to become operational in Africa.

2004

PRODUCT APPROVAL

FDA approves BARACLUDE® (entecavir).
U.S. Full Prescribing Information including Boxed WARNINGS  (PDF)

FDA approves ERBITUX® (cetuximab). 

2005

PRODUCT APPROVAL 

FDA approves REVLIMID® (lenalidomide)—an IMiD® compound. 
U.S. Full Prescribing Information including Boxed WARNINGS (PDF). 

CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS
CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS

2007

CLINICAL CENTER FOR CHILDREN WITH HIV/AIDS OPENS

The clinical center at the Bristol Myers Squibb Children’s Hospital at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, is dedicated to the research and treatment of children’s immune system disorders and infectious diseases. The Bristol Myers Squibb Pediatric Infectious Disease and Immunology Center is made possible by a $5 million gift from the Bristol Myers Squibb Foundation.

2007

PRODUCT APPROVAL

FDA approves IXEMPRA® (ixabepilone).

2008

PRODUCT ACQUISTION

Celgene gains VIDAZA® from Pharmion purchase. 

2008

RESEARCH COLLABORATION 

Celgene and Accerleron Pharma announce research collaboration to develop therapies for cancer and other rare diseases. 

RESEARCH COLLABORATION

2008

RESEARCH COLLABORATION 

Celgene and Accerleron Pharma announce research collaboration to develop therapies for cancer and other rare diseases. 

BRISTOL MYERS SQUIBB ACQUIRES MEDAREX
BRISTOL MYERS SQUIBB ACQUIRES MEDAREX

2009

BRISTOL MYERS SQUIBB ACQUIRES MEDAREX

Bristol Myers Squibb acquires Medarex, Inc., a biotech company and a partner since 2005. The acquisition significantly expands the company’s oncology and immunology pipeline.

2009

PRODUCT APPROVAL

FDA approves ONGLYZA® (saxagliptin).

2010

PRODUCT APPROVAL

FDA approves KOMBIGLYZE® XR (saxagliptin and metformin HCl extended‐release).

2010

PRODUCT ACQUISITION 

Celgene gains ISTODAX® (romidepsin) from Gloucester Pharmaceuticals purchase. 

2010

PRODUCT ACQUISITION 

Celgene gains ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) from Abraxis BioScience purchase. 
U.S. Full Prescribing Information including Boxed WARNINGS (PDF). 

2010

STRATEGIC COLLABORATION 

Celgene and Agios Pharmaceutical, Inc. announce global strategic collaboration focused on targeting cancer metabolism. 

STRATEGIC COLLABORATION

2010

STRATEGIC COLLABORATION 

Celgene and Agios Pharmaceutical, Inc. announce global strategic collaboration focused on targeting cancer metabolism. 

INVESTING IN THE FUTURE
INVESTING IN THE FUTURE

2013

INVESTING IN THE FUTURE

To expand its capabilities in development and manufacturing of biologics, the company announces a $250 million expansion of its manufacturing complex in Devens, Massachusetts.

2013

PRODUCT APPROVAL 

FDA approves POMALYST® (pomalidomide)—an IMiD® compound.
U.S. Full Prescribing Information including Boxed WARNING (PDF)

2013

RESEARCH COLLABORATION 

Celgene and bluebird bio enter into strategic research collaboration to develop novel therapies in oncology. 

RESEARCH COLLABORATION

2013

RESEARCH COLLABORATION 

Celgene and bluebird bio enter into strategic research collaboration to develop novel therapies in oncology. 

EXPANSION CONTINUES
EXPANSION CONTINUES

2014

EXPANSION CONTINUES

Construction begins on a new, large-scale biologics manufacturing facility in Cruiserath, Ireland, to be built on the grounds of its existing bulk pharmaceutical manufacturing plant.

A new state-of-the-art office campus is planned for Lawrenceville, New Jersey, to replace leased facilities in Plainsboro and West Windsor. 

2014

Product Approval

FDA approves OPDIVO® (nivolumab).

2015

BRISTOL MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

Bristol Myers Squibb is recognized as one of Dow Jones’ North America Index of Leading Sustainable Companies. Its efforts to promote economic, social and environmental sustainability are core to the mission and reflect its ongoing commitment to patients, employees and partners, the environment and communities around the world.

Bristol Myers Squibb Foundation Celebrates 60th Anniversary 

The Bristol Myers Squibb Foundation marks a quarter of a century helping millions of people across the world overcome serious diseases. 

BRISTOL MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

2015

BRISTOL MYERS SQUIBB NAMED A LEADING SUSTAINABLE COMPANY

Bristol Myers Squibb is recognized as one of Dow Jones’ North America Index of Leading Sustainable Companies. Its efforts to promote economic, social and environmental sustainability are core to the mission and reflect its ongoing commitment to patients, employees and partners, the environment and communities around the world.

Bristol Myers Squibb Foundation Celebrates 60th Anniversary 

The Bristol Myers Squibb Foundation marks a quarter of a century helping millions of people across the world overcome serious diseases. 

2015

PRODUCT APPROVAL
CELGENE ACQUIRES RECEPTOS
CELGENE ACQUIRES RECEPTOS

2015

CELGENE ACQUIRES RECEPTOS 

Celgene gains ZEPOSIA® (ozanimod) from Receptos purchase.    

2016

PRINCETON PIKE CAMPUS OPENS

This state-of-the-art campus in New Jersey features work space designed to foster greater innovation, productivity and collaboration. 

PRIX GALIEN AWARD

Bristol Myers Squibb is awarded the Prix Galien U.S. “Discovery of the Decade.” This is the third Prix Galien honor that the company has received, after being recognized for “Best Biotechnology Product” in 2012 and “Best Biotechnology Product” in 2015. 

PRINCETON PIKE CAMPUS OPENS

2016

PRINCETON PIKE CAMPUS OPENS

This state-of-the-art campus in New Jersey features work space designed to foster greater innovation, productivity and collaboration. 

PRIX GALIEN AWARD

Bristol Myers Squibb is awarded the Prix Galien U.S. “Discovery of the Decade.” This is the third Prix Galien honor that the company has received, after being recognized for “Best Biotechnology Product” in 2012 and “Best Biotechnology Product” in 2015. 

BRISTOL MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY
BRISTOL MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY

2017

BRISTOL MYERS SQUIBB CELEBRATES 130TH ANNIVERSARY 

Chairman and CEO Giovanni Caforio rings the New York Stock Exchange’s Closing Bell in celebration of the company milestone.

2017

PRODUCT APPROVAL  

2018

CELGENE ACQUIRES IMPACT BIOMEDICINES 

Celgene gains INREBIC® (fedratinib) from IMPACT BioMedicines purchase. 
U.S. Full Prescribing Information including Boxed WARNING (PDF)

CELGENE ACQUIRES IMPACT BIOMEDICINES

2018

CELGENE ACQUIRES IMPACT BIOMEDICINES 

Celgene gains INREBIC® (fedratinib) from IMPACT BioMedicines purchase. 
U.S. Full Prescribing Information including Boxed WARNING (PDF)

CELGENE ACQUIRES JUNO THERAPEUTICS
CELGENE ACQUIRES JUNO THERAPEUTICS

2018

CELGENE ACQUIRES JUNO THERAPEUTICS 

The acquisition contributes to Celgene’s stature as a premier cellular immunotherapy. 

2019

PRODUCT APPROVAL 

FDA approves REVLIMID® (lenalidomide) in combination with rituximab. 
U.S. Full Prescribing Information including Boxed WARNING (PDF)

2019

COMBINATION REGIMEN APPROVAL 

European Commission approves combination regimen for REVLIMID® (lenalidomide) and Imnovid® (pomalidomide). 
U.S. Full Prescribing Information including Boxed WARNING (PDF)

2019

PRODUCT APPROVAL 

2019

PRODUCT APPROVAL 

FDA approves REBLOZYL® (luspatercept-aamt).

2019

BRISTOL MYERS SQUIBB ACQUIRES CELGENE

Bristol Myers Squibb and Celgene come together to create a leading biopharma company positioned to address the needs of patients with serious diseases.

BRISTOL MYERS SQUIBB ACQUIRES CELGENE

2019

BRISTOL MYERS SQUIBB ACQUIRES CELGENE

Bristol Myers Squibb and Celgene come together to create a leading biopharma company positioned to address the needs of patients with serious diseases.

NEW CORPORATE BRAND AND VISION
NEW CORPORATE BRAND AND VISION

2020

NEW CORPORATE BRAND AND VISION 

As Bristol Myers Squibb builds for the future, we’re uniting around a single, powerful vision: transforming patients’ lives through science. Our new brand reflects the passion and precision we bring to pioneering life-saving medicines for people around the world and the compassion we bring to improving outcomes for the patients who need us most.

2020

PRODUCT APPROVALS

FDA approves ZEPOSIA® (ozanimod) and ONUREG® (azacitidine tablets).
ZESPOSIA U.S Full Prescribing Information (PDF)
ONUREG U.S. Full Prescribing Information (PDF)

2020

ACQUISITIONS

Bristol Myers Squibb acquires MyoKardia, strengthening the company’s leading cardiovascular franchise, and Forbius, adding a lead TGF-beta asset to the portfolio.

Myokardia Acquisition

2020

ACQUISITIONS

Bristol Myers Squibb acquires MyoKardia, strengthening the company’s leading cardiovascular franchise, and Forbius, adding a lead TGF-beta asset to the portfolio.